In a recent Nature elegant study, Wang et al. identified CD300ld, a novel functionally highly conserved tumor immunosuppressive receptor, highly expressed specifically on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as a key receptor in the regulation of recruitment and immunosuppressive function of PMN-MDSCs. Targeting CD300ld could remodel the tumor immune microenvironment, resulting in a broad-spectrum anti-tumor effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11190349 | PMC |
| http://dx.doi.org/10.1002/mco2.607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD300ld: A new target for tumor immunotherapy and new hope for cancer patients.
Sci Bull (Beijing)
September 2024
Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China; School of Physics, Peking University, Beijing 100871, China. Electronic address:
In a recent Nature elegant study, Wang et al. identified CD300ld, a novel functionally highly conserved tumor immunosuppressive receptor, highly expressed specifically on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as a key receptor in the regulation of recruitment and immunosuppressive function of PMN-MDSCs. Targeting CD300ld could remodel the tumor immune microenvironment, resulting in a broad-spectrum anti-tumor effect.
View Article and Find Full Text PDFTumor-driven immune suppression is a critical mechanism by which cancer cells evade the host immune system, leading to tumor growth and metastasis. The tumor immune microenvironment contains a large population of immune-suppressing myeloid cells, which play a key role in tumor development and drug resistance to existing immunotherapy. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are important components of the immunosuppressive microenvironment.
View Article and Find Full Text PDFTargeting PMN-MDSCs via CD300ld receptor for cancer immunotherapy.
Clin Transl Med
January 2024
Institute of Pediatrics of Children's Hospital of Fudan University, Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
CD300ld on neutrophils is required for tumour-driven immune suppression.
Nature
September 2023
Institute of Pediatrics of Children's Hospital of Fudan University, the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
The immune-suppressive tumour microenvironment represents a major obstacle to effective immunotherapy. Pathologically activated neutrophils, also known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), are a critical component of the tumour microenvironment and have crucial roles in tumour progression and therapy resistance. Identification of the key molecules on PMN-MDSCs is required to selectively target these cells for tumour treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!